某院医患纠纷档案管理现状

目的 探讨某三级甲等综合性医院医患纠纷档案管理现状及模式,为综合性医院医患纠纷的预防和处置提供管理思路.方法 采用回顾性分析方法调查该三级甲等综合性医院医患纠纷档案相关数据,同时采用德尔菲法和专家会议法等统计学方法分析,对某三级甲等综合性医院医患纠纷档案的管理进行现况调查和深入分析.结果 该三级甲等综合性医院医患纠纷档案通过专人及时、全面、完整、规范的收集和整理,辅以有效的科学立卷方案,迅速为该院医务行政人员,尤其是医疗质量管理人员提供便携的医疗服务.结论 医患纠纷档案的有效管理和合理利用,对于医患纠纷的解决提供指导和借鉴作用,各级医院,尤其是三级甲等综合性医院,应加强对医患纠纷档案的科学管理,通过科学有效的管理模式,提升医院的医疗质量.     

非小细胞肺癌组织中DNA切除修复交叉互补基因1mRNA的表达及其对预后的影响

Objective To investigate the level of ERCC1 mRNA expression in non-small cell lung cancer and analyze the influencing factors of the survival of patients after operation. Methods The level of ERCC1 mRNA expression was quantified in sixty pairs of non-small cell lung cancer tissue and their matched normal lung tissues by real-time PCR assay. The survival of patients was analyzed by univariate Kaplan-Meier and Cox regression analysis. Results The level of ERCC1 mRNA expression in cancer tissues ( -7.85 ±3.86) was significantly higher than that in matched normal ones ( - 11. 19 ±5.03;t=3.973, P=0.000). Up-regulation of ERCC1 mRNA was found in 43 of 60 (71.7% ) lung cancer tissues compared with that in the matched normal lung tissues (17 of 60, 28.3% ). The univariate survival analysis by Kaplan-Meier method showed that the survival rate of patients with high ERCC1 mRNA expression was lower than that in the patients with low expression of ERCC1 mRNA (P=0.000). Patients with lymph node metastasis, smoking, cancer family history, or high pathological grade had significantly shorter survaival time than those without lymph node metastasis, smoking, cancer family history, or with low pathological grade. Cox regression survival analysis showed that the level of ERCC1 mRNA expression, lymph node metastasis, smoking, and pathological grade were significant independent factors affecting the survival rate. Conclusions Non-small cell lung cancer patients with up-regulated ERCC1 expression have a poor survival. The expression of ERCC1 mRNA, lymph node metastasis, pathological grade, cancer family history and smoking can be used as prognostic indicator of non-small cell lung cancer.